Biomarker & Intervention Discovery

Hypothyroidism

This page lists 8 druggable gene targets, 33 approved or trial-tested drug candidates and 15 recent clinical trials for Hypothyroidism, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

US DALYs1.70MWHO GHE 2021 · all ages
Global DALYs13.92MWHO GHE 2021 · worldwide
US mortality57.7K deaths/yrWHO GHE 2021
Global mortality221.3K deaths/yrWHO GHE 2021 · worldwide
Spontaneous remissionHashimoto's (most common cause) is irreversible in majority; spontaneous recovery in <5%; subclinical hypothyroidism…
Best-intervention remissionT4 monotherapy normalizes TSH in nearly all patients and resolves symptoms in ~60%; up to 40% of T4-treated patients…
Gap sizeModerate — within the treated population, a large minority are inadequately treated by the standard-of-care T4…
Primary barrierframing/practice
Full remission profile →

Remission & chronicity

Spontaneous remission
Hashimoto's (most common cause) is irreversible in majority; spontaneous recovery in <5%; subclinical hypothyroidism spontaneously normalizes in ~30-40% of cases within 2 years without treatment
Best-intervention remission
T4 monotherapy normalizes TSH in nearly all patients and resolves symptoms in ~60%; up to 40% of T4-treated patients remain symptomatic despite normalized TSH; T4+T3 combination or desiccated thyroid extract (DTE) preferred by ~50% of patients in blinded preference trials
Gap size
Moderate — within the treated population, a large minority are inadequately treated by the standard-of-care T4 monotherapy approach
Primary barrier
framing/practice
Up to 40% of patients remain symptomatic on T4 despite guideline-defined adequate treatment; T3 combination and DTE are rarely offered in primary care despite guideline acknowledgment that a trial may be appropriate; TSH-only monitoring misses tissue-level hypothyroidism

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

CTLA4 32DIO1 1DIO2 0TG 31THRA 146THRB 253TPO 55TSHR 294
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TREMELIMUMAB ↓ inhibits Mechanistic
IPILIMUMAB ↓ inhibits Mechanistic
CYCLOSPORINE ? unclear Mechanistic
ATEZOLIZUMAB ? unclear Mechanistic
VISILIZUMAB ? unclear Mechanistic
BLEOMYCIN ? unclear Mechanistic
ANTIBIOTIC ? unclear Mechanistic
METHIMAZOLE ? unclear Mechanistic
RETRO-INVERSO PEPTIDE ? unclear Mechanistic
MELPHALAN ? unclear Mechanistic
RECOMBINANT FAS LIGAND ? unclear Mechanistic
ZALIFRELIMAB ↓ inhibits Mechanistic
RIBAVIRIN ? unclear Mechanistic
ANTI-THYMOCYTE GLOBULIN ? unclear Mechanistic
QUAVONLIMAB ↓ inhibits Mechanistic
COMPOUND 32 [PMID: 20471253] ↓ inhibits Mechanistic
SIROLIMUS ? unclear Mechanistic
BISPECIFIC ANTIBODY ? unclear Mechanistic
CADONILIMAB ↓ inhibits Mechanistic
APLITHIANINE A ↓ inhibits Mechanistic
PEGINTERFERON ALFA-2A ? unclear Mechanistic
INOSINE 5'-MONOPHOSPHATE DEHYDROGENASE INHIBITOR FF-10501-01 ? unclear Mechanistic
ABATACEPT ? unclear Mechanistic
WORTMANNIN ? unclear Mechanistic
ERFONRILIMAB ↓ inhibits Mechanistic
THALIDOMIDE ? unclear Mechanistic
FF-10501-01 ? unclear Mechanistic
PEGINTERFERON ALFA-2B ? unclear Mechanistic
TETRADECANOYLPHORBOL ACETATE ? unclear Mechanistic
DEHYDRATED ALCOHOL ? unclear Mechanistic
PREDNISONE ? unclear Mechanistic
CHEMBL5291170 ↓ inhibits Mechanistic 31000.0 nM (Kd)
Therapeutic Agent Effect Direction Evidence Tier Potency Source
PROPYLTHIOURACIL ↓ inhibits Mechanistic

Pipeline results not yet available for this target. Run the pipeline to populate.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
GENISTEIN ? unclear Mechanistic
VITAMIN A ? unclear Mechanistic
RECOMBINANT TRANSFORMING GROWTH FACTOR-BETA 1 ? unclear Mechanistic
DEXAMETHASONE ? unclear Mechanistic
ACEBUTOLOL ? unclear Mechanistic
AZACITIDINE ? unclear Mechanistic
VACCINE ? unclear Mechanistic
AMINOGLYCOSIDE ANTIBIOTIC ? unclear Mechanistic
FLUORODEOXYGLUCOSE F18 ? unclear Mechanistic
CALCITRIOL ? unclear Mechanistic
PREDNISONE ? unclear Mechanistic
HEXAMETHYLENEBISACETAMIDE ? unclear Mechanistic
PREDNISOLONE ? unclear Mechanistic
ALDESLEUKIN ? unclear Mechanistic
PEGINTERFERON ALFA-2A ? unclear Mechanistic
OCTREOTIDE ACETATE ? unclear Mechanistic
DEHYDRATED ALCOHOL ? unclear Mechanistic
ISOTRETINOIN ? unclear Mechanistic
RETINOIC ACID AGENT ? unclear Mechanistic
GAMMA-INTERFERON ? unclear Mechanistic
PHENYTOIN SODIUM ? unclear Mechanistic
AMIODARONE HYDROCHLORIDE ? unclear Mechanistic
HEXAMETHYLENE BISACETAMIDE ? unclear Mechanistic
POLYETHYLENE GLYCOL 4000 ? unclear Mechanistic
ROSIGLITAZONE ? unclear Mechanistic
TECHNETIUM TC 99M SESTAMIBI ? unclear Mechanistic
BISPECIFIC ANTIBODY ? unclear Mechanistic
AMINOGLUTETHIMIDE ? unclear Mechanistic
ANTIDEPRESSANT AGENT ? unclear Mechanistic
ADENOVIRUS VECTOR ? unclear Mechanistic
TRETINOIN ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ASPIRIN ? unclear Mechanistic
LIOTHYRONINE ↑ activates Mechanistic 0.1 nM (Kd)
LEVOTHYROXINE ↑ activates Mechanistic
LIOTHYRONINE SODIUM ↑ activates Mechanistic
TIRATRICOL ? unclear Mechanistic 0.14 nM (IC50)
DEXTROTHYROXINE ↑ activates Mechanistic
DEXTROTHYROXINE SODIUM ↑ activates Mechanistic
LEVOTHYROXINE SODIUM ? unclear Mechanistic
CHEMBL111953 ↓ inhibits Mechanistic 490.0 nM (Kd)
CHEMBL109430 ↓ inhibits Mechanistic 5.2 nM (Kd)
CHEMBL109279 ↓ inhibits Mechanistic 93.0 nM (Kd)
CHEMBL110158 ↓ inhibits Mechanistic 330.0 nM (Kd)
SOBETIROME ↓ inhibits Mechanistic 1.8 nM (Kd)
CHEMBL112087 ↓ inhibits Mechanistic 200.0 nM (Kd)
CHEMBL83953 ↓ inhibits Mechanistic 39000.0 nM (IC50)
CHEMBL86271 ↓ inhibits Mechanistic 1800.0 nM (IC50)
CHEMBL82131 ↓ inhibits Mechanistic 18100.0 nM (IC50)
CHEMBL85322 ↓ inhibits Mechanistic 69000.0 nM (IC50)
CHEMBL83829 ↓ inhibits Mechanistic 930.0 nM (IC50)
CHEMBL97187 ↓ inhibits Mechanistic 1400.0 nM (Kd)
CHEMBL318132 ↓ inhibits Mechanistic 112.0 nM (Kd)
CHEMBL97613 ↓ inhibits Mechanistic 430.0 nM (Kd)
CHEMBL98135 ↓ inhibits Mechanistic 1400.0 nM (Kd)
CHEMBL264527 ↓ inhibits Mechanistic 240.0 nM (Kd)
CHEMBL160883 ↓ inhibits Mechanistic 820.0 nM (IC50)
CHEMBL160703 ↓ inhibits Mechanistic 1400.0 nM (IC50)
AMIODARONE ↓ inhibits Mechanistic 650.0 nM (IC50)
CHEMBL157885 ↓ inhibits Mechanistic 4500.0 nM (IC50)
DETROTHYRONINE ↓ inhibits Mechanistic 0.24 nM (IC50)
CHEMBL39174 ↓ inhibits Mechanistic 1.4 nM (IC50)
THYROPROPIC ACID ↓ inhibits Mechanistic 0.041 nM (IC50)
CHEMBL40738 ↓ inhibits Mechanistic 130.0 nM (IC50)
CHEMBL289965 ↓ inhibits Mechanistic 9.7 nM (IC50)
CHEMBL41036 ↓ inhibits Mechanistic 25.0 nM (IC50)
CHEMBL289343 ↓ inhibits Mechanistic 0.1 nM (IC50)
CHEMBL418432 ↓ inhibits Mechanistic 0.76 nM (IC50)
CHEMBL41314 ↓ inhibits Mechanistic 0.14 nM (IC50)
CHEMBL125946 ↑ activates Mechanistic 1500.0 nM (EC50)
CHEMBL124205 ↑ activates Mechanistic 12.0 nM (EC50)
CHEMBL419016 ↓ inhibits Mechanistic 2.4 nM (Kd)

Showing top 40 of 146 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
METHYL PARATHIONE ? unclear Mechanistic
DIENOCHLOR ? unclear Mechanistic
AXITIROME ? unclear Mechanistic
3-METHYLCHOLANTHRENE ? unclear Mechanistic
CHEMBL:CHEMBL577415 ? unclear Mechanistic
DYCLONINE HYDROCHLORIDE ? unclear Mechanistic
LEVOTHYROXINE ↑ activates Mechanistic
ORTHO-PHTHALALDEHYDE ? unclear Mechanistic
QUINALIZARIN ? unclear Mechanistic
CHEMBL:CHEMBL297304 ? unclear Mechanistic
CHEMBL:CHEMBL1493528 ? unclear Mechanistic
RESMETIROM ↑ activates Mechanistic
CLOSANTEL ? unclear Mechanistic
IDARUBICIN ? unclear Mechanistic
FUMARPROTOCETRARIC ACID ? unclear Mechanistic
DIPYRIDAMOLE ? unclear Mechanistic
CHEMBL:CHEMBL1341830 ? unclear Mechanistic
CARUBICIN ? unclear Mechanistic
ALBUTEROL SULFATE ? unclear Mechanistic
PRIMAQUINE ? unclear Mechanistic
DEXTROTHYROXINE SODIUM ↑ activates Mechanistic
SOBETIROME ↑ activates Mechanistic 0.1 nM (Kd)
METHYLENE BLUE ANHYDROUS ? unclear Mechanistic
HEXACHLOROPHENE ? unclear Mechanistic
CHEMBL:CHEMBL1465049 ? unclear Mechanistic
COMPOUND 16G [PMID: 35507418] ↑ activates Mechanistic
CHLOROTHALONIL ? unclear Mechanistic
SLAZINIC ACID ? unclear Mechanistic
TRIAMTERENE ? unclear Mechanistic
CHEMBL:CHEMBL601952 ? unclear Mechanistic
CHEMBL:CHEMBL578741 ? unclear Mechanistic
CIRAZOLINE ? unclear Mechanistic
CHEMBL:CHEMBL581044 ? unclear Mechanistic
DAUNORUBICIN HYDROCHLORIDE ? unclear Mechanistic
RT3 ↑ activates Mechanistic
CHEMBL:CHEMBL592124 ? unclear Mechanistic
VK-2809 ↑ activates Mechanistic
CHEMBL:CHEMBL602969 ? unclear Mechanistic
EPROTIROME ↑ activates Mechanistic
TOLONIUM CHLORIDE ? unclear Mechanistic

Showing top 40 of 253 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CARBIMAZOLE ↓ inhibits Mechanistic
PROPYLTHIOURACIL ↓ inhibits Mechanistic 3380.0 nM (IC50)
TRETINOIN ? unclear Mechanistic
METHIMAZOLE ↓ inhibits Mechanistic
CHEMBL4278946 ↓ inhibits Mechanistic 3900.0 nM (IC50)
CHEMBL4282403 ↓ inhibits Mechanistic 6000.0 nM (IC50)
CHEMBL4482878 ↓ inhibits Mechanistic 4000.0 nM (IC50)
CHEMBL333928 ↓ inhibits Mechanistic 42000.0 nM (IC50)
CHEMBL4637728 ↓ inhibits Mechanistic 30000.0 nM (IC50)
CHEMBL4645343 ↓ inhibits Mechanistic 5300.0 nM (IC50)
CHEMBL4633000 ↓ inhibits Mechanistic 5900.0 nM (IC50)
CHEMBL4753981 ↓ inhibits Mechanistic 2200.0 nM (IC50)
CHEMBL4792720 ↓ inhibits Mechanistic 6300.0 nM (IC50)
CHEMBL4751166 ↓ inhibits Mechanistic 59000.0 nM (IC50)
CHEMBL4755252 ↓ inhibits Mechanistic 12300.0 nM (IC50)
CHEMBL4869433 ↓ inhibits Mechanistic 700.0 nM (IC50)
CHEMBL4859908 ↓ inhibits Mechanistic 640.0 nM (IC50)
CHEMBL4855030 ↓ inhibits Mechanistic 2000.0 nM (IC50)
CHEMBL4855931 ↓ inhibits Mechanistic 710.0 nM (IC50)
CHEMBL4846080 ↓ inhibits Mechanistic 2300.0 nM (IC50)
CHEMBL4853722 ↓ inhibits Mechanistic 1100.0 nM (IC50)
CHEMBL4863015 ↓ inhibits Mechanistic 1100.0 nM (IC50)
CHEMBL4871587 ↓ inhibits Mechanistic 1800.0 nM (IC50)
CHEMBL4855956 ↓ inhibits Mechanistic 6700.0 nM (IC50)
CHEMBL4878518 ↓ inhibits Mechanistic 1900.0 nM (IC50)
CHEMBL4862053 ↓ inhibits Mechanistic 1100.0 nM (IC50)
CHEMBL4860429 ↓ inhibits Mechanistic 1700.0 nM (IC50)
CHEMBL4877407 ↓ inhibits Mechanistic 14000.0 nM (IC50)
CHEMBL4859470 ↓ inhibits Mechanistic 21000.0 nM (IC50)
PF-06282999 ↓ inhibits Mechanistic 990.0 nM (IC50)
CHEMBL5200638 ↓ inhibits Mechanistic 590.0 nM (IC50)
CHEMBL5181827 ↓ inhibits Mechanistic 4200.0 nM (IC50)
CHEMBL5182747 ↓ inhibits Mechanistic 8100.0 nM (IC50)
CHEMBL5185576 ↓ inhibits Mechanistic 1500.0 nM (IC50)
CHEMBL5172456 ↓ inhibits Mechanistic 1300.0 nM (IC50)
CHEMBL5197968 ↓ inhibits Mechanistic 1390.0 nM (IC50)
CHEMBL5197383 ↓ inhibits Mechanistic 3400.0 nM (IC50)
CHEMBL5175091 ↓ inhibits Mechanistic 1400.0 nM (IC50)
CHEMBL5207346 ↓ inhibits Mechanistic 4200.0 nM (IC50)
CHEMBL5186129 ↓ inhibits Mechanistic 1900.0 nM (IC50)

Showing top 40 of 55 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
PENTACHLOROPHENOL ? unclear Mechanistic
THYROTROPIN ALFA ↑ activates Mechanistic
CILOSTAZOL ? unclear Mechanistic
ALPHA-NAPHTHOFLAVONE ? unclear Mechanistic
GRAMINE ? unclear Mechanistic
TESTOSTERONE PROPIONATE ? unclear Mechanistic
SB 222200 ? unclear Mechanistic
URAPIDIL ? unclear Mechanistic
CHEMBL:CHEMBL312032 ? unclear Mechanistic
CHEMBL:CHEMBL578276 ? unclear Mechanistic
CHEMBL:CHEMBL606166 ? unclear Mechanistic
AM-630 ? unclear Mechanistic
CHEMBL:CHEMBL607309 ? unclear Mechanistic
LEVALBUTEROL ? unclear Mechanistic
CHEMBL:CHEMBL140220 ? unclear Mechanistic
ICI-199441 ? unclear Mechanistic
LASALOCID A SODIUM ? unclear Mechanistic
CLOSANTEL ? unclear Mechanistic
DIPYRIDAMOLE ? unclear Mechanistic
ANTISERUM ? unclear Mechanistic
ISOPROTERENOL ? unclear Mechanistic
SEROTONIN ? unclear Mechanistic
NMDA ? unclear Mechanistic
BERGAMOTTIN ? unclear Mechanistic
3,6-DIMETHOXYFLAVONE ? unclear Mechanistic
L-733,060 ? unclear Mechanistic
TYRPHOSTIN AG 879 ? unclear Mechanistic
CARBONYL CYANIDE M-CHLOROPHENYLHYDRAZONE ? unclear Mechanistic
CP-339818 ? unclear Mechanistic
DICHLOROPHEN ? unclear Mechanistic
CLORGILINE ? unclear Mechanistic
DEXPROPRANOLOL ? unclear Mechanistic
TYRPHOSTIN A9 ? unclear Mechanistic
CHEMBL:CHEMBL429095 ? unclear Mechanistic
CLIOXANIDE ? unclear Mechanistic
PIPERONYL BUTOXIDE ? unclear Mechanistic
CHEMBL:CHEMBL1456848 ? unclear Mechanistic
KARANJIN ? unclear Mechanistic
THYROTROPIN ↑ activates Mechanistic
KINETIN ? unclear Mechanistic

Showing top 40 of 294 agents ranked by evidence tier.


Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Hypothyroidism: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

NCT07900737 Phase: 4 Started: 2025-07-24

Primary hypothyroidism is a common condition, affecting nearly 10% of the general population. Its treatment is levothyroxine, a synthetic thyroid hormone with a half-life of nearly eight days. Optimal absorption of levothyroxine occurs when it is taken on an empty stomach. It is generally recommende...

NCT06345339 Phase: 2/3 Started: 2024-04-26

This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism and are currently stabilized (i.e., in-range thyroid-stimulating hormone \[TSH\]) on synthetic T4 treatment. This study will also therefore evaluate the...

NCT07754370 Phase: 4 Started: 2025-11-02

This randomized controlled trial compared high-dose and moderate-dose levothyroxine as initial therapy for neonates with primary congenital hypothyroidism. One hundred one infants were randomized to receive either approximately 12.85 or 7.65 µg/kg/day. Thyroid function and dose adjustments were asse...

NCT07747103 Phase: 3 Started: 2026-06-30

The North Star study is a multi-center, Phase 3, open-label, single-arm clinical study to evaluate the Efficacy and Safety of North Star therapy.

NCT06731764 Phase: 2/3 Started: 2024-12-10

Hypothyroidism is a common condition, more frequent in females, associated with excess of cardiovascular risk and poor quality of life not completely abrogated by treatment with levothyroxine. There is an unmet need to define a safe, effective, and feasible regimen to be applied in large trials aime...

NCT06073665 Phase: 4 Started: 2024-01-31

Our overall goal is to determine the clinical consequences of allowing greater flexibility in LT4 dosing in older individuals who take LT4.

NCT07421869 Phase: N/A Started: 2024-06-12

The goal of this study is to find out whether hypothyroidism caused by immune checkpoint inhibitors (ICIs) can recover after stopping the ICIs. The study also aims to identify factors that can help predict which patients will be able to stop taking thyroid hormone replacement. The main questions the...

NCT05712421 Phase: 2 Started: 2023-02-28

The North Star study is a multi-center, Phase 2, double-blind, randomized, parallel group clinical study to evaluate the safe and effective dose conversion from Levothyroxine to North Star therapy.

NCT07380854 Phase: N/A Started: 2022-02-27

The goal of this clinical trial is to find out whether levothyroxine reduces complications and improves the prognosis of patients with subclinical hypothyroidism (SCH) undergoing coronary artery bypass grafting (CABG). The main questions this study aims to answer are: • Does levothyroxine reduce maj...

NCT06757712 Phase: N/A Started: 2025-01-01

This study will be conducted to compare between the effect of nonlinear and linear periodized training on quality of life in females with hypothyroidism.

NCT05823012 Phase: 2 Started: 2023-05-15

This is a non-randomized, open-label, single arm, self-controlled study of XP-8121 (levothyroxine sodium) to determine a target dose conversion factor from stably dosed oral levothyroxine to XP-8121 (levothyroxine sodium) in patients with hypothyroidism and to assess the safety and tolerability of X...

NCT06276205 Phase: 3 Started: 2024-03-01

The goal of this clinical trial is to study the improvement of lipid levels in hypothyroid individuals after staring treatment. The main question it aims to answer is: • whether adding Vitamin D to standard therapy has any additional benefits Participants will be given Vitamin D in replacement doses...

NCT05682482 Phase: 3 Started: 2022-10-07

Hypothyroidism is common, affecting 5% of the general population, for which levothyroxine (LT4) monotherapy is the standard treatment. Despite normalized serum thyroid hormone levels, 10-15% of LT4 treated patients have various persistent complaints, the most important of which is tiredness. This co...

NCT06826248 Phase: Early 1 Started: 2024-07-02

STUDY OBJECTIVES 1. To assess the safety of Darqeen capsule for the management of Hypothyroidism 2. Evaluate the efficacy of Darqeen capsule for the management of Hypothyroidism 3. To provide an alternative cost-effective treatment for the management of females suffering from hypothyroidism. NULL HY...

NCT05412979 Phase: 2 Started: 2022-04-29

ST-1891-201 is a multicenter, randomized, double-blind, partial crossover, Phase 2 study evaluating the safety and efficacy of hormone replacement therapy with ST-1891 compared to levothyroxine in patients with primary hypothyroidism.


Agents Found By Disease-Level Search

Searched directly from “Hypothyroidism” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 8-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

33 agents shown (approved or with trial evidence) — 28 not found by the gene-target search above.

Levothyroxine

Approved · 11 trials · source: ClinicalTrials.gov, Open Targets
NCT04124705 NCT05412979 NCT01950260

levothyroxine sodium

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT05823012 NCT00921050 NCT03880578

L-carnitineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01769157

Armour® ThyroidNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04124705

ST-1891NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05412979

MNP groupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02280330

Quantitative POC TSH KitNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01921452

Qualitative POC TSH KitNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01921452

Third generation TSH KitNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01921452

Liothyronine, Sodium

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01800617

LT3 (liothyronine)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05682482

management of therapy complicationsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00336102

Eltroxin administrationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06154382

ThyroxineNOT in gene-target list

Unknown · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT05385029

Serum thyroid function testsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04860622

TRH (Thyrotropin Releasing Hormone)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00054756

Assesment of thyroïd functionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04831957

Liothyronine

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT04782856

D-THIO (Deprescribing Thyroid Hormone In Older Adults)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06629272

L-thyroxineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00524238

Clinical Pharmacist Intervention GroupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06408909

Levothyroxine/Liothyronine once dailyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06731764

Levothyroxine/Liothyronine twice dailyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06731764

Levothyroxine sodium new formulationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01916304

Brand Name Levothyroxine (Synthroid)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00403390

Generic formulation of LevothyroxineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00403390

iodinated contrast agentsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02766283

THYROTROPIN

Approved · 0 trials · source: Open Targets

OMEGA-3-ACID ETHYL ESTERSNOT in gene-target list

Approved · 0 trials · source: Open Targets

CHOLESTYRAMINENOT in gene-target list

Approved · 0 trials · source: Open Targets

FENOFIBRATENOT in gene-target list

Approved · 0 trials · source: Open Targets

MECASERMINNOT in gene-target list

Approved · 0 trials · source: Open Targets

THYROGLOBULINNOT in gene-target list

Approved · 0 trials · source: Open Targets

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.